Displaying One Session
ESMO Colloquium
Date
23.09.2020
Chairs
- Myung-Ju Ahn (Seoul, Korea, Republic of)
- Martin Reck (Grosshansdorf, Germany)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
ESMO Colloquium
Is Osimertinib the best single agent if 1st line?
Speakers
- Myung-Ju Ahn (Seoul, Korea, Republic of)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
ESMO Colloquium
Should chemotherapy be combined upfront with EGFR TKI?
Speakers
- Ross Soo (Singapore, Singapore)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
ESMO Colloquium
Is a combination of anti-angiogenic with EFGR TKI a new standard
Speakers
- Martin Reck (Grosshansdorf, Germany)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
ESMO Colloquium
Do immune check point work in EGFR TKI?
Speakers
- Edward B. Garon (Santa Monica, CA, United States of America)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
ESMO Colloquium
In a multiline setting, what is the best sequencing?
Speakers
- Enriqueta Felip (Barcelona, Spain)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
ESMO Colloquium
Conclusions
Speakers
- Myung-Ju Ahn (Seoul, Korea, Republic of)
ESMO Colloquium supported by Eli Lilly and Company: Are single agent TKIs still Standard of Care in EGFR mutant Non-Small Cell Lung Cancer or should they be combined with other agents?
ESMO Colloquium
Live Q&A
Speakers
- Myung-Ju Ahn (Seoul, Korea, Republic of)
- Martin Reck (Grosshansdorf, Germany)